35345-09-6 Usage
Heterocyclic compound
Imidazole ring system The compound contains a ring structure made up of both carbon and nitrogen atoms, which is characteristic of imidazole.
Methyl group attachment
4th carbon atom A methyl group (CH3) is attached to the fourth carbon atom of the imidazole ring, which influences its chemical properties and reactivity.
Chlorophenyl group
Phenyl ring with a chlorine substituent The compound features a phenyl ring (a six-carbon ring structure) with a chlorine atom attached to it, which contributes to its unique properties and potential applications.
Potential applications
Pharmaceutical and chemical industries Due to its unique structure and properties, 2-(4-CHLOROPHENYL)-4-METHYL-3H-IMIDAZOLE may be used in the synthesis of other organic compounds or as a starting material for new pharmaceutical drug development.
Biological activities
Relevance in drug discovery and development The compound may possess biological activities that make it relevant for research in drug discovery and development, potentially leading to new therapeutic agents.
Check Digit Verification of cas no
The CAS Registry Mumber 35345-09-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,5,3,4 and 5 respectively; the second part has 2 digits, 0 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 35345-09:
(7*3)+(6*5)+(5*3)+(4*4)+(3*5)+(2*0)+(1*9)=106
106 % 10 = 6
So 35345-09-6 is a valid CAS Registry Number.
InChI:InChI=1/C10H9ClN2/c1-7-6-12-10(13-7)8-2-4-9(11)5-3-8/h2-6H,1H3,(H,12,13)
35345-09-6Relevant articles and documents
Discovery of Imidazole-Based Inhibitors of Plasmodium falciparum cGMP-Dependent Protein Kinase
Aylor, Samantha O.,Bhanot, Purnima,Bheemanaboina, Rammohan R. Yadav,Childers, Wayne E.,Colussi, Dennis J.,De Souza, Mariana Laureano,Eck, Tyler,Gonzalez, Mariana Lozano,Gordon, John,Kreiss, Tamara,Lee, Patricia,Mahmood, Shams Ul,Pybus, Brandon S.,Rotella, David P.,Roth, Alison,Siekierka, John J.
supporting information, p. 1962 - 1967 (2021/12/01)
The discovery of new targets for the treatment of malaria, in particular those aimed at the pre-erythrocytic stage in the life cycle, advanced with the demonstration that orally administered inhibitors of Plasmodium falciparum cGMP-dependent protein kinase (PfPKG) could clear infection in a murine model. This enthusiasm was tempered by unsatisfactory safety and/or pharmacokinetic issues found with these chemotypes. To address the urgent need for new scaffolds, this paper presents initial structure-activity relationships in an imidazole scaffold at four positions, representative in vitro ADME, hERG characterization, and cell-based antiparasitic activity. This series of PfPKG inhibitors has good in vitro PfPKG potency, low hERG activity, and cell-based antiparasitic activity against multiple Plasmodium species that appears to be correlated with the in vitro potency.
